Compounds
AssigneeBoehringer Ingelheim International GmbH
InventorsKlaus Rudolf, Daniel Bischoff, Georg Dahmann, Matthias Grauert, Raimund Kuelzer, Bernd Wellenzohn
Life of this patent
Estimating the term…
Abstract
This invention relates to compounds of formula I their use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment. A, B, X, R1, R2, R3 have meanings given in the description.
Claims12
A compound of formula I
- in which
- A and B independently represent CH or N;
- R1 represents aryl, heteroaryl, C1-8alkyl, C3-7cycloalkyl or —O—C1-8alkyl which latter five groups are optionally substituted with one or more substituents selected from halogen, —CN, C1-3alkyl and —O—C1-3alkyl;
- R2 and R3 independently represent —H, halogen, —CN, C1-5alkyl, C3-5cycloalkyl or —O—C1-5alkyl which latter three groups are optionally substituted with one or more fluorine atoms;
- X represents
- Ar1 represents
- Ar2 represents
- D represents S or O;
- R4 and R5 independently represent —H, halogen, —OH, —CN, —NH2, C1-5alkyl, phenyl, —NH—C1-5alkyl, —N(C1-5alkyl)2, —O—C1-5alkyl, —COO—C1-5alkyl, —CONH(C1-5alkyl), —CON(C1-5alkyl)2, —NHCONH—C1-5alkyl, —NHCON(C1-5alkyl)2 or —NHCO—C1-5alkyl which latter eleven groups are optionally substituted with one or more substituents selected from halogen and —OH;
- R6 represents —H or C1-3alkyl;
- or a physiologically acceptable salt thereof.
A compound selected from the group consisting of
- or a physiologically acceptable salt thereof.
Dependencies are inferred from the claim text.